Search Results - "Reesink, Hendrik"

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3 by Zeuzem, Stefan, Dusheiko, Geoffrey M, Salupere, Riina, Mangia, Alessandra, Flisiak, Robert, Hyland, Robert H, Illeperuma, Ari, Svarovskaia, Evguenia, Brainard, Diana M, Symonds, William T, Subramanian, G. Mani, McHutchison, John G, Weiland, Ola, Reesink, Hendrik W, Ferenci, Peter, Hézode, Christophe, Esteban, Rafael

“…In patients with HCV genotypes 2 and 3, sofosbuvir plus ribavirin was administered for 12 weeks in patients with genotype 2 and for 24 weeks in those with…”
Get full text

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial by van der Ree, Meike H, MD, de Vree, J Marleen, MD, Stelma, Femke, MD, Willemse, Sophie, MD, van der Valk, Marc, MD, Rietdijk, Svend, MD, Molenkamp, Richard, PhD, Schinkel, Janke, MD, van Nuenen, Ad C, BSc, Beuers, Ulrich, Prof, Hadi, Salah, MD, Harbers, Marten, PhD, van der Veer, Eva, MSc, Liu, Kai, PhD, Grundy, John, PhD, Patick, Amy K, PhD, Pavlicek, Adam, PhD, Blem, Jacqueline, BSc, Huang, Michael, MD, Grint, Paul, MD, Neben, Steven, PhD, Gibson, Neil W, PhD, Kootstra, Neeltje A, PhD, Reesink, Hendrik W, Dr

“…Summary Background miR-122 is an important host factor for hepatitis C virus (HCV) replication. The aim of this study was to assess the safety and…”
Get full text

Treatment of HCV Infection by Targeting MicroRNA by Janssen, Harry L.A, Reesink, Hendrik W, Lawitz, Eric J, Zeuzem, Stefan, Rodriguez-Torres, Maribel, Patel, Keyur, van der Meer, Adriaan J, Patick, Amy K, Chen, Alice, Zhou, Yi, Persson, Robert, King, Barney D, Kauppinen, Sakari, Levin, Arthur A, Hodges, Michael R

“…In this phase 2 trial, an antisense oligonucleotide was tested in the treatment of chronic hepatitis C virus infection. The oligonucleotide was designed to…”
Get full text

Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues by Jansen, L., Kootstra, Neeltje A., van Dort, Karel A., Takkenberg, R. Bart, Reesink, Hendrik W., Zaaijer, Hans L.

“…Background. Treatment of patients with chronic hepatitis B (CHB) with nucleos(t)ide analogues (NAs) suppresses hepatitis B virus (HBV) DNA production but does…”
Get full text

Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study) by Brouwer, Willem Pieter, Xie, Qing, Sonneveld, Milan J., Zhang, Ningping, Zhang, Qin, Tabak, Fehmi, Streinu‐Cercel, Adrian, Wang, Ji‐Yao, Idilman, Ramazan, Reesink, Hendrik W., Diculescu, Mircea, Simon, Krzysztof, Voiculescu, Mihai, Akdogan, Meral, Mazur, Wlodzimierz, Reijnders, Jurrien G.P., Verhey, Elke, Hansen, Bettina E., Janssen, Harry L.A.

“…Entecavir (ETV) is a potent inhibitor of hepatitis B viral replication, but long‐term therapy may be required. We investigated whether adding on pegylated…”
Get full text

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection by Sherman, Kenneth E, Flamm, Steven L, Afdhal, Nezam H, Nelson, David R, Sulkowski, Mark S, Everson, Gregory T, Fried, Michael W, Adler, Michael, Reesink, Hendrik W, Martin, Marie, Sankoh, Abdul J, Adda, Nathalie, Kauffman, Robert S, George, Shelley, Wright, Christopher I, Poordad, Fred

“…In patients with chronic infection with HCV genotype 1 and undetectable HCV at weeks 4 and 12 of treatment, a 24-week regimen that included telaprevir,…”
Get full text

Human intrahepatic CD69 + CD8+ T cells have a tissue resident memory T cell phenotype with reduced cytolytic capacity by Stelma, Femke, de Niet, Annikki, Sinnige, Marjan J., van Dort, Karel A., van Gisbergen, Klaas P. J. M., Verheij, Joanne, van Leeuwen, Ester M. M., Kootstra, Neeltje A., Reesink, Hendrik W.

“…Tissue resident memory T cells (T RM ) have been identified in various tissues, however human liver T RM to date remain unidentified. T RM can be recognized by…”
Get full text

Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients by Kieffer, Tara L., Sarrazin, Christoph, Miller, Janice S., Welker, Martin W., Forestier, Nicole, Reesink, Hendrik W., Kwong, Ann D., Zeuzem, Stefan

“…Telaprevir (VX‐950) is an orally active, specifically targeted antiviral therapy for hepatitis C virus (HCV) that has been shown to profoundly reduce plasma…”
Get full text

Telaprevir for Previously Treated Chronic HCV Infection by McHutchison, John G, Manns, Michael P, Muir, Andrew J, Terrault, Norah A, Jacobson, Ira M, Afdhal, Nezam H, Heathcote, E. Jenny, Zeuzem, Stefan, Reesink, Hendrik W, Garg, Jyotsna, Bsharat, Mohammad, George, Shelley, Kauffman, Robert S, Adda, Nathalie, M.D, Adrian M. Di Bisceglie

“…In this randomized trial of patients infected with hepatitis C virus genotype 1 in whom a sustained virologic response was not achieved after initial therapy,…”
Get full text

Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients by van der Ree, Meike H., van der Meer, Adriaan J., de Bruijne, Joep, Maan, Raoel, van Vliet, Andre, Welzel, Tania M., Zeuzem, Stefan, Lawitz, Eric J., Rodriguez-Torres, Maribel, Kupcova, Viera, Wiercinska-Drapalo, Alcija, Hodges, Michael R., Janssen, Harry L.A., Reesink, Hendrik W.

“…•We present the long-term safety and efficacy outcome of patients treated with anti-miR therapy.•No long-term safety issues were observed among…”
Get full text

Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study by Younossi, Zobair M, Stepanova, Maria, Zeuzem, Stefan, Dusheiko, Geoffrey, Esteban, Rafael, Hezode, Christophe, Reesink, Hendrik W, Weiland, Ola, Nader, Fatema, Hunt, Sharon L

“…Background & Aim Interferon (IFN) negatively impacts patients’ well-being and patient-reported outcomes (PROs). Our aim was to assess PROs during treatment…”
Get full text

Plasma MicroRNA Levels Are Associated With Hepatitis B e Antigen Status and Treatment Response in Chronic Hepatitis B Patients by van der Ree, Meike H., Jansen, Louis, Kruize, Zita, van Nuenen, Ad C., van Dort, Karel A., Takkenberg, R. Bart, Reesink, Hendrik W., Kootstra, Neeltje A.

“…Background. Hepatitis B virus (HBV) modulates microRNA (miRNA) expression to support viral replication. The aim of this study was to identify miRNAs associated…”
Get full text

Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti‐MicroRNA‐122, RG‐101 by Stelma, Femke, van der Ree, Meike H., Sinnige, Marjan J., Brown, Anthony, Swadling, Leo, de Vree, J. Marleen L., Willemse, Sophie B., van der Valk, Marc, Grint, Paul, Neben, Steven, Klenerman, Paul, Barnes, Eleanor, Kootstra, Neeltje A., Reesink, Hendrik W.

“…MicroRNA‐122 is an important host factor for the hepatitis C virus (HCV). Treatment with RG‐101, an N‐acetylgalactosamine‐conjugated anti‐microRNA‐122…”
Get full text

Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study by Reesink, Hendrik W., Zeuzem, Stefan, Weegink, Christine J., Forestier, Nicole, van Vliet, Andre, van de Wetering de Rooij, Jeroen, McNair, Lindsay, Purdy, Susan, Kauffman, Robert, Alam, John, Jansen, Peter L.M.

“…Background & Aims: VX-950 specifically inhibits the NS3·4A protease of hepatitis C and has antiviral activity in vitro. This phase I, placebo-controlled,…”
Get full text

Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir by Stelma, Femke, de Niet, Annikki, Plat-Sinnige, Marjan J. Tempelmans, Jansen, Louis, Takkenberg, R. Bart, Reesink, Hendrik W., Kootstra, Neeltje A., van Leeuwen, Ester M. M.

“…Background. The role of natural killer (NK) cells in the process of hepatitis B virus (HBV) surface antigen (HBsAg) clearance and whether their phenotype is…”
Get full text

Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C by Forestier, Nicole, Reesink, Hendrik W., Weegink, Christine J., McNair, Lindsay, Kieffer, Tara L., Chu, Hui‐May, Purdy, Susan, Jansen, Peter L.M., Zeuzem, Stefan

“…Telaprevir (VX‐950), an inhibitor of the hepatitis C virus (HCV) NS3/4A protease, substantially decreased plasma HCV RNA levels in a prior clinical study. The…”
Get full text

The history of buffy coat platelet concentrates: The Dutch story by Meer, Pieter F., Reesink, Hendrik W., Korte, Dirk, Loos, Johannes A., Klei, Thomas R. L.

“…The buffy coat method as a source for platelet concentrates was developed in the 1970s and is still used in many blood centres around the world. Development of…”
Get full text

Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy by de Niet, Annikki, Stelma, Femke, Jansen, Louis, Sinnige, Marjan J, Remmerswaal, Ester B.M, Takkenberg, R. Bart, Kootstra, Neeltje A, Reesink, Hendrik W, van Lier, Rene A.W, van Leeuwen, Ester M.M

“…Graphical abstract…”
Get full text

Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study by Brouwer, Willem P, Chan, Henry L Y, Lampertico, Pietro, Hou, Jinlin, Tangkijvanich, Pisit, Reesink, Hendrik W, Zhang, Wenhong, Mangia, Alessandra, Tanwandee, Tawesak, Montalto, Giuseppe, Simon, Kris, Ormeci, Necati, Chen, Liang, Tabak, Fehmi, Gunsar, Fulya, Flisiak, Robert, Ferenci, Peter, Akdogan, Meral, Akyuz, Filiz, Hirankarn, Nattiya, Jansen, Louis, Wong, Vincent Wai-Sun, Soffredini, Roberta, Liang, Xieer, Chen, Shalom, Groothuismink, Zwier M A, Santoro, Rosanna, Jaroszewicz, Jerzy, Ozaras, Resat, Kozbial, Karin, Brahmania, Mayur, Xie, Qing, Chotiyaputta, Watcharasak, Xun, Qi, Pazgan-Simon, Monika, Oztas, Erkin, Verhey, Elke, Montanari, Noé R, Sun, Jian, Hansen, Bettina E, Boonstra, Andre, Janssen, Harry L A

“…Abstract Background (Pegylated) Interferon ([Peg]IFN) therapy leads to response in a minority of chronic hepatitis B (CHB) patients. Host genetic determinants…”
Get full text

Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir by Thomas, Xiomara V, de Bruijne, Joep, Sullivan, James C, Kieffer, Tara L, Ho, Cynthia K Y, Rebers, Sjoerd P, de Vries, Michel, Reesink, Hendrik W, Weegink, Christine J, Molenkamp, Richard, Schinkel, Janke

“…Telaprevir, a hepatitis C virus NS3/4A protease inhibitor has significantly improved sustained viral response rates when given in combination with pegylated…”
Get full text